Non-Hodgkin Lymphoma Primary Mediastinal Large B-cell Lymphoma

New Reference: Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma

2023-06-07

  • Study

    Phase II, open-label, multicenter, multicohort study
    The patient had to have experienced relapse or be ineligible for ASCT
    Pembrolizumab (n=53)

  • Efficacy

    cORR: 41.5% [22 of 53 pts]
    CR: 20.8% [ 11of 53 pts]
    mDoR: NR [NR-NR]
    median PFS: 4.3 mos

  • Safety

    Grade≥3: Neutropenia (13.2%), astenia (1.9%), AST increased (1.9%)


    • BLOOD, VOL 142, ISSUE 2, P141-145, JUL 2023

    Zinzani Pier Luigi et al. Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170

    http://doi.org/10.1182/blood.2022019340

    Reviewed by Elvin CHALABİYEV, MD on SEP 10, 2023